I assigned a ‘Buy’ rating to Medtronic (NYSE: MDT ) in March 2025, highlighting strength in cardiac ablation solutions. I think the company’s decision to spin off its diabetes business is a near-term catalyst for its stock price. I am upgradingAnalyst’s Disclosure: I/we have a beneficial long position in the shares of MDT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seekin ...